Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6796 to 6810 of 7680 results

  1. Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

    Discontinued [GID-TA10186]

    Technology appraisal guidance
    Discontinued

  2. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued [GID-TAG330]

    Technology appraisal guidance
    Discontinued

  3. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued [GID-TA10891]

    Technology appraisal guidance
    Discontinued

  4. Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]

    Discontinued [GID-TA10212]

    Technology appraisal guidance
    Discontinued

  5. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued [GID-TA10045]

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued [GID-TA10321]

    Technology appraisal guidance
    Discontinued

  7. Alzheimer's disease (early) - gantenerumab [ID6142]

    In development [GID-TA11269] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued [GID-TA10277]

    Technology appraisal guidance
    Discontinued

  9. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued [GID-TAG444]

    Technology appraisal guidance
    Discontinued

  10. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued [GID-TAG375]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued [GID-TA10193]

    Technology appraisal guidance
    Discontinued

  12. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued [GID-TAG399]

    Technology appraisal guidance
    Discontinued

  13. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued [GID-TA10353]

    Technology appraisal guidance
    Discontinued

  14. Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]

    Discontinued [GID-TAG407]

    Technology appraisal guidance
    Discontinued

  15. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued [GID-TA10318]

    Technology appraisal guidance
    Discontinued